Childhood-onset systemic lupus erythematosus: an update

  title={Childhood-onset systemic lupus erythematosus: an update},
  author={R Ezequiel Borgia and Earl D. Silverman},
  journal={Current Opinion in Rheumatology},
  • R. Borgia, E. Silverman
  • Published 1 September 2015
  • Medicine, Biology, Psychology
  • Current Opinion in Rheumatology
Purpose of reviewThis is an update of the main studies published in the last year regarding biomarkers, advances in pathophysiology, lupus nephritis as well as outcomes and therapies in childhood-onset systemic lupus erythematosus (cSLE). Recent findingsSome progress in the pathophysiology of cSLE was made in the past year. Although biomarkers were studied in lupus nephritis and neuropsychiatric lupus, none of the proposed biomarkers was shown to be a significant improvement over current… 

Biomarkers in Childhood-Onset Systemic Lupus Erythematosus.

Impact of the longitudinal quantitative assessment of juvenile systemic lupus erythematosus severity on the disease outcome

An early diagnosis combined with longitudinal quantitative assessment is a key determinant for an optimal management and a minimal damage development and contributes to the continuous evaluation of the disease state.

Pentraxin-3 levels are associated with vasculitis and disease activity in childhood-onset systemic lupus erythematosus

Results support that PTX3 reflects active cutaneous vasculitis in cSLE and correlates with disease activity, and investigate its relation with diseaseActivity, damage, clinical features, laboratory parameters and medications.

Systemic Lupus Erythematosus: contributory factors and diagnosis

Pregnancy outcome appears to be worse in people with SLE whose disease flares up during pregnancy, and treatment includes corticosteroids and anti-malarial drugs.

Anasarca as the initial symptom in a Japanese girl with Sjögren’s syndrome

Elevated levels of serum C-reactive protein, ferritin and plasma D-dimer suggested that systemic inflammation caused anasarca by both decreased production of albumin and hyperpermeability associated with vascular endothelial damage similar to systemic capillary leak syndrome.

Evaluation of pulmonary artery pressure in patients with juvenile systemic lupus erythematosus (jSLE).

Overall, PASP and mPAP were significantly higher in jSLE patients compared to healthy controls and Prospective studies with ethnically diverse cohorts could give more insight on the relevance of PAP and PHT in patients with jSle.

Cross-sectional study of plasma Axl, ferritin, IGFBP4 and sTNFR2 as biomarkers of disease activity in childhood-onset SLE: A study of the Pediatric Nephrology Research Consortium

In childhood-onset SLE patients, plasma ferritin and Axl perform better than traditional yardsticks in identifying disease activity, either global or renal.

Stability of novel urinary biomarkers used for lupus nephritis

RAIL biomarkers are stable following short-term storage at clinically relevant conditions following shipping on dry or wet ice exposure and addition of two freeze-thaw cycles, with excellent Spearman Correlation coefficients under all conditions.

Hepatitis A virus vaccination in childhood-onset systemic lupus erythematosus

It is concluded that inactivated hepatitis A vaccine is safe and well tolerated in childhood-onset systemic lupus erythematosus patients, with no adverse events or increase in activity.



Biomarkers for Childhood-Onset Systemic Lupus Erythematosus

Novel biomarkers for cSLE include cell-bound complement activation products, some genomic profiles, and urinary proteins such as neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and others which can be used for monitoring disease activity and response to treatment.

New insights into the pathogenesis and management of lupus in children

This review will present current knowledge of the innate and adaptive immune responses in cSLE and the optimal patient management that aims to control the disease.

Advances in biomarkers for paediatric rheumatic diseases

The search for biomarkers in paediatric rheumatic diseases, particularly juvenile idiopathic arthritis (JIA), childhood lupus nephritis (LN), and juvenile idiopathic inflammatory myopathies (JIIMs)

Safety and Efficacy of Rituximab in Childhood-onset Systemic Lupus Erythematosus and Other Rheumatic Diseases

Investigation of the safety and efficacy of RTX in a variety of pediatric autoimmune diseases, especially systemic lupus erythematosus, found it can be safely administered to children and appears to contribute to decreased disease activity and steroid burden.

Presentation and outcome of paediatric membranous non-proliferative lupus nephritis

The outcome of non-proliferative MLN in systemic lupus erythematosus was good, and the majority of patients did not require aggressive immunosuppressive treatment to reach a stable disease state on low-dose steroid treatment.

Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients.

The aim of the study was to evaluate the efficacy and safety of belimumab in the real-life experience of a single tertiary referral center of rheumatology after the first year of licensed use in Italy.

Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children

Select brain-reactive proteins in the blood are associated with cognitive performance and the presence of cSLE-NCD, cross-sectionally and over time.

Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: from bench to bedside

DNA microarray technology led to the discovery that the interleukin (IL)-1 gene signature is associated with systemic juvenile idiopathic arthritis (sJIA) and the use of IL-1 blockade with anakinra in this disease.

Obesity and Cytokines in Childhood-Onset Systemic Lupus Erythematosus

The finding suggests that obesity may contribute to the increase of serum TNF-α levels in cSLE, and was associated with obesity and body fat content in childhood-onset SLE.

Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide

This pilot study demonstrates that a systematically administered course of rituximab and cyclophosphamide over an eighteen month period provided sustained relief for patients with childhood onset SLE which was maintained over a sixty month period, while minimizing the need for corticosteroids, without excessive toxicity.